Gastrointestinal Bleeding in Critically Ill Cancer Patients

Causes and Management
  • David M. Richards
  • William A. RossEmail author
Living reference work entry


Cancer patients are at higher risk factor for gastrointestinal (GI) hemorrhage. In addition, the cancer diagnosis predicts poorer outcomes from the hemorrhage. Management is complicated by the expanded differential for sources of bleeding not only from the cancer but its therapy. In addition, cancer or its therapy can lead to bone marrow suppression with resulting thrombocytopenia that can exacerbate blood loss. New targeted therapy agents have unique properties leading to unusual adverse events like perforation and immune-mediated colitis. However, management strategies exist and are of proven benefit in these challenging patients. Endoscopy plays a critical role not only in establishing etiology but in control of hemorrhage. Direct tumor bleeding is problematic but does respond to endoscopic measures although recurrence rates are high. Additional nonendoscopic therapy directed toward tumor may be beneficial in reducing recurrence rates. Overall prognosis in GI bleeding is good, but cancer patients have higher risk of rebleeding and mortality.


Gastrointestinal hemorrhage Anemia Endoscopy Colitis Targeted therapy Immune checkpoint inhibitors Thrombocytopenia Variceal bleeding Anticoagulation Neutropenia 


  1. 1.
    Ananthakrishnan AN, McGinley EL, Saeian K. Higher hospital volume is associated with lower mortality in acute nonvariceal upper-GI hemorrhage. Gastrointest Endosc. 2009;70:422–32.CrossRefGoogle Scholar
  2. 2.
    Aoki T, Nagata N, Niikura R, Shimbo T, Tanaka S, Sekine K, Kishida Y, Watanabe K, Sakurai T, Yokoi C, et al. Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2015;13:488–494 e481.CrossRefGoogle Scholar
  3. 3.
    Aoki T, Nagata N, Shimbo T, Niikura R, Sakurai T, Moriyasu S, Okubo H, Sekine K, Watanabe K, Yokoi C, et al. Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2016;14:1562–1570 e1562.CrossRefGoogle Scholar
  4. 4.
    Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017;28:2932–42.CrossRefGoogle Scholar
  5. 5.
    Assi H, Abdel-Samad N. Severe gastrointestinal hemorrhage during targeted therapy for advanced breast carcinoma. Curr Oncol. 2014;21:e732–5.CrossRefGoogle Scholar
  6. 6.
    Barkun AN, Martel M. The role of early colonoscopy in acute lower GI bleeding: summarizing conflicting data in the presence of society recommendations. Gastrointest Endosc. 2017;86:118–9.CrossRefGoogle Scholar
  7. 7.
    Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010;11:373–82.CrossRefGoogle Scholar
  8. 8.
    Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol. 2012;25:106–18.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68.CrossRefGoogle Scholar
  10. 10.
    Brandler J, Baruah A, Zeb M, Mehfooz A, Pophali P, Wong Kee Song L, AbuDayyeh B, Gostout C, Mara K, Dierkhising R, et al. Efficacy of over-the-scope clips in management of high-risk gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2018;16:690–696 e691.CrossRefGoogle Scholar
  11. 11.
    Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2014;32:1210–7.CrossRefGoogle Scholar
  12. 12.
    Camus M, Jensen DM, Ohning GV, Kovacs TO, Jutabha R, Ghassemi KA, Machicado GA, Dulai GS, Jensen ME, Gornbein JA. Comparison of three risk scores to predict outcomes of severe lower gastrointestinal bleeding. J Clin Gastroenterol. 2016;50:52–8.CrossRefGoogle Scholar
  13. 13.
    Cao D, Guo CH, Liu JW, Yang X, Li Q. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer. Tumori. 2015;101:46–51.CrossRefGoogle Scholar
  14. 14.
    Cavallaro LG, Monica F, Germana B, Marin R, Sturniolo GC, Saia M. Time trends and outcome of gastrointestinal bleeding in the Veneto region: a retrospective population based study from 2001 to 2010. Dig Liver Dis. 2014;46:313–7.CrossRefGoogle Scholar
  15. 15.
    Cortes J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Munoz E, Perez J, Dawood S, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol. 2012;23:1130–7.CrossRefGoogle Scholar
  16. 16.
    Crist M, Hansen E, Chablani L, Guancial E. Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2017;120:151–62.CrossRefGoogle Scholar
  17. 17.
    Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology. 2013;144:1384–93, 1393 e1381-1382; quiz e1318-1389CrossRefGoogle Scholar
  18. 18.
    Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139:69–79.CrossRefGoogle Scholar
  19. 19.
    Duan SJ, Gao ZM, Wang PL, Gong BC, Huang HW, Luo L, Wang X, Xing YN, Xu HM, Liu FN. Rare upper gastrointestinal hemorrhage of cetuximab: a case report. Medicine (Baltimore). 2017;96:e9391.CrossRefGoogle Scholar
  20. 20.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, et al. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008;14:2088–94.CrossRefGoogle Scholar
  21. 21.
    Fujihara S, Mori H, Kobara H, Nishiyama N, Ayaki M, Ohata R, Ueda N, Sugimoto M, Kakehi Y, Masaki T. Uncommon gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a report of four cases. Oncol Lett. 2015;10:2895–8.CrossRefGoogle Scholar
  22. 22.
    Fujihara S, Mori H, Kobara H, Suenaga T, Hayashida Y, Sugimoto M, Kakehi Y, Masaki T. Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a case report. BMC Nephrol. 2013;14:141.CrossRefGoogle Scholar
  23. 23.
    Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases. Hepatology. 2017;65:310–35.CrossRefGoogle Scholar
  24. 24.
    Ghassemi KA, Kovacs TO, Jensen DM. Gastric acid inhibition in the treatment of peptic ulcer hemorrhage. Curr Gastroenterol Rep. 2009;11:462–9.CrossRefGoogle Scholar
  25. 25.
    Gonzales P, Klusewitz S, Marowske J, Gancayco J, Osswald MB, Setlik R. Everolimus implicated in case of severe gastrointestinal hemorrhage. Case Rep Oncol Med. 2017;2017:3657812.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, Rotondano G, Hucl T, Dinis-Ribeiro M, Marmo R, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2015;47:a1–46.CrossRefGoogle Scholar
  27. 27.
    Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut. 2011;60:1327–35.CrossRefGoogle Scholar
  28. 28.
    Heller SJ, Tokar JL, Nguyen MT, Haluszka O, Weinberg DS. Management of bleeding GI tumors. Gastrointest Endosc. 2010;72:817–24.CrossRefGoogle Scholar
  29. 29.
    Honda T, Kobayashi H, Saiki M, Sogami Y, Miyashita Y, Inase N. Gastroesphageal variceal hemorrhage induced by metastatic liver tumor of lung cancer. Case Rep Oncol. 2012;5:644–50.CrossRefGoogle Scholar
  30. 30.
    Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Ann Intern Med. 1997;127:1062–71.CrossRefGoogle Scholar
  31. 31.
    Jairath V, Kahan BC, Gray A, Dore CJ, Mora A, James MW, Stanley AJ, Everett SM, Bailey AA, Dallal H, et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet. 2015;386:137–44.CrossRefGoogle Scholar
  32. 32.
    Kouanda AM, Somsouk M, Sewell JL, Day LW. Urgent colonoscopy in patients with lower GI bleeding: a systematic review and meta-analysis. Gastrointest Endosc. 2017;86:107–117 e101.CrossRefGoogle Scholar
  33. 33.
    Krishna SG, Rao BB, Thirumurthi S, Lee JH, Ramireddy S, Guindani M, Ross WA. Safety of endoscopic interventions in patients with thrombocytopenia. Gastrointest Endosc. 2014;80:425–34.CrossRefGoogle Scholar
  34. 34.
    Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P, Intensive Care in Hematological, Oncological Patients Collaborative Group. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21:89.CrossRefGoogle Scholar
  35. 35.
    Kyaw M, Tse Y, Ang D, Ang TL, Lau J. Embolization versus surgery for peptic ulcer bleeding after failed endoscopic hemostasis: a meta-analysis. Endosc Int Open. 2014;2:E6–E14.CrossRefGoogle Scholar
  36. 36.
    Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107:345–60; quiz 361CrossRefGoogle Scholar
  37. 37.
    Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012;107:1190–5; quiz 1196CrossRefGoogle Scholar
  38. 38.
    Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–61.CrossRefGoogle Scholar
  39. 39.
    Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Ponce M, Quintero E, Perez-Aisa MA, Gisbert JP, Bujanda L, Castro M, Munoz M, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther. 2011;33:585–91.CrossRefGoogle Scholar
  40. 40.
    Lawal TO, Farris AB, El-Rayes BF, Subramanian RM, Kim HS. Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt. Clin Colorectal Cancer. 2012;11:224–7.CrossRefGoogle Scholar
  41. 41.
    Marmo R, Del Piano M, Rotondano G, Koch M, Bianco MA, Zambelli A, Di Matteo G, Grossi E, Cipolletta L, Investigators P, et al. Mortality from nonulcer bleeding is similar to that of ulcer bleeding in high-risk patients with nonvariceal hemorrhage: a prospective database study in Italy. Gastrointest Endosc. 2012;75:263–72, 272 e261CrossRefGoogle Scholar
  42. 42.
    Marmo R, Koch M, Cipolletta L, Bianco MA, Grossi E, Rotondano G, PNED 1 and PNED 2 Investigators. Predicting mortality in patients with in-hospital nonvariceal upper GI bleeding: a prospective, multicenter database study. Gastrointest Endosc. 2014;79:741–749 e741.CrossRefGoogle Scholar
  43. 43.
    Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, Kojima T, Ohtsu A, Yoshino T, Doi T, et al. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer. 2018;18:120.CrossRefGoogle Scholar
  44. 44.
    Murakami N, Yoshimoto S, Matsumoto F, Ueno T, Ito Y, Watanabe S, Kobayashi K, Harada K, Kitaguchi M, Sekii S, et al. Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab. J Cancer Res Clin Oncol. 2015;141:177–84.CrossRefGoogle Scholar
  45. 45.
    Myers RP, Papay KD, Shaheen AA, Kaplan GG. Relationship between hospital volume and outcomes of esophageal variceal bleeding in the United States. Clin Gastroenterol Hepatol. 2008;6:789–98.CrossRefGoogle Scholar
  46. 46.
    Namikawa T, Hanazaki K. Clinicopathological features and treatment outcomes of metastatic tumors in the stomach. Surg Today. 2014;44:1392–9.CrossRefGoogle Scholar
  47. 47.
    Niikura R, Nagata N, Shimbo T, Sakurai T, Aoki T, Moriyasu S, Sekine K, Okubo H, Watanabe K, Yokoi C, et al. Adverse events during bowel preparation and colonoscopy in patients with acute lower gastrointestinal bleeding compared with elective non-gastrointestinal bleeding. PLoS One. 2015;10:e0138000.CrossRefGoogle Scholar
  48. 48.
    Oakland K, Guy R, Uberoi R, Hogg R, Mortensen N, Murphy MF, Jairath V, Collaborative UKLGB. Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit. Gut. 2018;67:654–62.PubMedGoogle Scholar
  49. 49.
    Oakland K, Jairath V, Uberoi R, Guy R, Ayaru L, Mortensen N, Murphy MF, Collins GS. Derivation and validation of a novel risk score for safe discharge after acute lower gastrointestinal bleeding: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:635–43.CrossRefGoogle Scholar
  50. 50.
    Patel SD, Desai R, Patel U, Singh S, Patel Z, Patel N, Zhang A, Panwala AH, Khan VN, Singh G, et al. Thirty-day readmissions after upper and lower gastrointestinal hemorrhage: a national perspective in the United States. J Clin Gastroenterol. epub March 20 2018.Google Scholar
  51. 51.
    Pittayanon R, Rerknimitr R, Barkun A. Prognostic factors affecting outcomes in patients with malignant GI bleeding treated with a novel endoscopically delivered hemostatic powder. Gastrointest Endosc. 2018;87:994–1002.CrossRefGoogle Scholar
  52. 52.
    Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Prabhu-Coelho N, et al. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointest Endosc. 2018;88(1):55–61.CrossRefGoogle Scholar
  53. 53.
    Razzaghi A, Barkun AN. Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. J Clin Gastroenterol. 2012;46:482–6.CrossRefGoogle Scholar
  54. 54.
    Richter-Schrag HJ, Glatz T, Walker C, Fischer A, Thimme R. First-line endoscopic treatment with over-the-scope clips significantly improves the primary failure and rebleeding rates in high-risk gastrointestinal bleeding: a single-center experience with 100 cases. World J Gastroenterol. 2016;22:9162–71.CrossRefGoogle Scholar
  55. 55.
    Robertson M, Majumdar A, Boyapati R, Chung W, Worland T, Terbah R, Wei J, Lontos S, Angus P, Vaughan R. Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems. Gastrointest Endosc. 2016;83:1151–60.CrossRefGoogle Scholar
  56. 56.
    Roshan Afshar I, Sadr MS, Strate LL, Martel M, Menard C, Barkun AN. The role of early colonoscopy in patients presenting with acute lower gastrointestinal bleeding: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2018;11:1756283X18757184.CrossRefGoogle Scholar
  57. 57.
    Schatz RA, Rockey DC. Gastrointestinal bleeding due to gastrointestinal tract malignancy: natural history, management, and outcomes. Dig Dis Sci. 2017;62:491–501.CrossRefGoogle Scholar
  58. 58.
    Sengupta N, Tapper EB. Derivation and internal validation of a clinical prediction tool for 30-day mortality in lower gastrointestinal bleeding. Am J Med. 2017;130:601 e601–8.CrossRefGoogle Scholar
  59. 59.
    Shafi MA, Bresalier RS. The gastrointestinal complications of oncologic therapy. Gastroenterol Clin N Am. 2010;39:629–47.CrossRefGoogle Scholar
  60. 60.
    Sheibani S, Kim JJ, Chen B, Park S, Saberi B, Keyashian K, Buxbaum J, Laine L. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. Aliment Pharmacol Ther. 2013;38:144–50.CrossRefGoogle Scholar
  61. 61.
    Shih AW, Crowther MA. Reversal of direct oral anticoagulants: a practical approach. Hematology Am Soc Hematol Educ Program. 2016;2016:612–9.CrossRefGoogle Scholar
  62. 62.
    Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009;8:225–30.CrossRefGoogle Scholar
  63. 63.
    Strate LL, Ayanian JZ, Kotler G, Syngal S. Risk factors for mortality in lower intestinal bleeding. Clin Gastroenterol Hepatol. 2008;6:1004–10; quiz 1955-CrossRefGoogle Scholar
  64. 64.
    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol. 2016;111:459–74.CrossRefGoogle Scholar
  65. 65.
    Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Schein J, et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol. 2018;93:664–71.CrossRefGoogle Scholar
  66. 66.
    Sung JJ, Chiu PC, Chan FKL, Lau JY, Goh KL, Ho LH, Jung HY, Sollano JD, Gotoda T, Reddy N, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2018;67(10):1757–68.CrossRefGoogle Scholar
  67. 67.
    Tey J, Soon YY, Koh WY, Leong CN, Choo BA, Ho F, Vellayappan B, Lim K, Tham IW. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:25797–805.CrossRefGoogle Scholar
  68. 68.
    Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368:11–21.CrossRefGoogle Scholar
  69. 69.
    Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230–40.CrossRefGoogle Scholar
  70. 70.
    Wuerth BA, Rockey DC. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis. Dig Dis Sci. 2018;63:1286–93.CrossRefGoogle Scholar
  71. 71.
    Yarris JP, Warden CR. Gastrointestinal bleeding in the cancer patient. Emerg Med Clin North Am. 2009;27:363–79.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Gastroenterology Hepatology & NutritionUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations